Feldmann D, Guittard C, Georges M D, Houdayer C, Magnier C, Claustres M, Couderc R
Laboratoire de biochimie, Hôpital A.-Trousseau, 26, avenue du Dr-A.-Netter, 75571 Paris cedex 12.
Ann Biol Clin (Paris). 2001 May-Jun;59(3):277-83.
Routine determination of mutations in cystic fibrosis requires accurate, rapid, reliable and low-cost methods, permitting the simultaneous detection of multiple mutations. The Elucigene CF20 kit developped by Cellmark Diagnostics, uses multiplex ARMS, which allows the screening for 20 CFTR gene mutations (deltaF508, G542X, N1303K, 1717-1G>A, G551D, W1282X, R553X, deltaI507, 1078delT, 2183AA>G, 3849+10kbC>T, R1162X, 621+1G>T, R334W, R347P, 3659delC, R117H, S1251N, E60X, A455E ) in a work day without specific instrumentation. The kit distinguishes between homozygotes and heterozygotes for deltaF508, but not for rare mutations. The kit detects from 68 to 92% of defective alleles in Caucasians. We evaluate the kit in a blind study in two independent laboratories. Thirty blood samples and thirty mouthwash samples from CF patients, carriers and unaffected individuals were analysed by the Elucigene CF20 kit. All the samples were previously analysed by denaturing gradient gel electrophoresis and sequencing. The Elucigene CF20 kit consists of three multiplexes. Each mutiplex contains ARMS specific primers for six to eight mutations and two control reactions. The absence of the upper control fragment indicates that a repeat test is required. We demonstrated a first time amplification rate of 98.3%: of the 60 samples tested, one required a reamplification. Results compared with the reference method demonstrated that in all cases where one or more of the 20 mutations detected by the kit were present in the test set, the kit accurately identified them. Reproducibility was assessed by repeating the analysis of a blood and mouthwash sample five times. Cross reactivity between R117C and R117H, R117P and R117H, R347P and R347H, deltaI507 and deltaF508, G551D and R553X were evaluated. Only a cross reactivity between R347P and R347H was observed. The kit is specially useful for first line study of patients and carrier identification.
囊性纤维化突变的常规检测需要准确、快速、可靠且低成本的方法,以便能同时检测多个突变。Cellmark Diagnostics公司研发的Elucigene CF20试剂盒采用多重扩增不应变突变系统(ARMS),可在无需特定仪器的情况下,在一个工作日内筛查20种囊性纤维化跨膜传导调节因子(CFTR)基因突变(ΔF508、G542X、N1303K、1717 - 1G>A、G551D、W1282X、R553X、ΔI507、1078delT、2183AA>G、3849 + 10kbC>T、R1162X、621 + 1G>T、R334W、R347P、3659delC、R117H、S1251N、E60X、A455E)。该试剂盒可区分ΔF508的纯合子和杂合子,但对于罕见突变则无法区分。在白种人中,该试剂盒能检测出68%至92%的缺陷等位基因。我们在两个独立实验室进行的一项盲法研究中对该试剂盒进行了评估。使用Elucigene CF20试剂盒对30份来自囊性纤维化患者、携带者和未受影响个体的血液样本及30份漱口水样本进行了分析。所有样本之前均已通过变性梯度凝胶电泳和测序进行了分析。Elucigene CF20试剂盒由三个多重反应体系组成。每个多重反应体系包含针对6至8个突变的ARMS特异性引物以及两个对照反应。缺乏上部对照片段表明需要重复检测。我们首次证明扩增率为98.3%:在检测的60个样本中,有1个需要重新扩增。与参考方法比较的结果表明,在试剂盒检测出的20种突变中,只要测试集中存在一种或多种突变,该试剂盒就能准确识别。通过对一份血液样本和一份漱口水样本重复分析5次来评估重现性。对R117C与R117H、R117P与R117H、R347P与R347H、ΔI507与ΔF508、G551D与R553X之间的交叉反应性进行了评估。仅观察到R347P与R347H之间存在交叉反应。该试剂盒对于患者的一线研究和携带者鉴定特别有用。